16 related articles for article (PubMed ID: 38477603)
1. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
2. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
3. STK11 mutation impacts CD1E expression to regulate the differentiation of macrophages in lung adenocarcinoma.
Zhang Q; Feng J; Liu K; Yang X; Huang Y; Tang B
Immun Inflamm Dis; 2023 Jul; 11(7):e958. PubMed ID: 37506141
[TBL] [Abstract][Full Text] [Related]
4. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
5. MPZL1 Promotes Lung Adenocarcinoma Progression by Enhancing Tumor Proliferation, Invasion, Migration, and Suppressing Immune Function via Transforming Growth Factor-β1.
Wang A; Fan F; Zang C; Li C; Hong H; Wang Z; Gao Y; Chen L; Yu X; Zhou C; Zhao C
Hum Gene Ther; 2023 Jun; 34(11-12):540-553. PubMed ID: 37183407
[TBL] [Abstract][Full Text] [Related]
6. ANGPT1 promotes M1 macrophage polarization and inhibits lung adenocarcinoma progression by inhibiting the TGF-β signalling pathway.
Liu G; Zhang H
Gen Physiol Biophys; 2024 Mar; 43(2):121-138. PubMed ID: 38477603
[TBL] [Abstract][Full Text] [Related]
7. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]